Study of Combination Therapy With the MEK Inhibitor, cobimetinib, Immune Checkpoint Blockade, atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies. Here, MAP2K7 is linked to cancer.